LPA/LPA1-mediated fibroblast proliferation and migration are implicated in the pathogenesis of IPF; thus, targeting LPA1 pathway is a new potential therapeutic strategy to treat IPF. Here, LPAR1 is linked to idiopathic pulmonary fibrosis.